TwinBeech Capital’s Kyntra Bio KYNB Stock Holding History

TwinBeech Capital’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,805	Closed	-$717K	–	643
2021 Q3	$717K	Buy	+2,805	New	+$994K	0.05%	375

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

TwinBeech Capital's KYNB Position: Q4 2021 in Review

TwinBeech Capital sold out of Kyntra Bio (KYNB) in Q4 2021, closing a stake of 2,805 shares — an estimated $717K sold.

TwinBeech Capital first reported a position in KYNB in Q3 2021 and held it in 1 quarter. The position peaked at $717K in Q3 2021. 162 funds tracked by Wall St. Rank hold KYNB as of Q4 2021.

TwinBeech Capital reported no remaining Kyntra Bio position as of Q4 2021 after selling out during the quarter.
TwinBeech Capital sold 2,805 Kyntra Bio shares in Q4 2021, an estimated $717K.
TwinBeech Capital first reported a position in Kyntra Bio in Q3 2021 and held it in 1 quarter.
TwinBeech Capital's Kyntra Bio position peaked at $717K in Q3 2021.
162 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2021.

Based on TwinBeech Capital's 13F filing for Q4 2021, filed 14 Feb 2022.